BMC Cancer

Table 1 Correlation of XIAP with clinico-pathological parameters in Breast Cancer

From: XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis

	Total		XIAP Over-expression		XIAP Low-expression		P value
	N	%	N	%	N	%	P value
Total Number of Cases	964		284	29.5	680	70.5
Age Groups
< 50	306	31.7	87	28.4	219	71.6	0.6320
> 50	658	68.3	197	29.9	461	70.1
Tumor size^a
≤ 2 cm	208	22.1	46	22.1	162	77.9	0.0044
> 2 cm	731	77.9	236	32.1	498	67.9
Lymph Nodes involvement^a
Negative	300	33.3	81	27.0	219	73.0	0.3914
Positive	602	66.7	179	29.7	423	70.3
Metastasis^a
M0	776	89.8	225	29.0	551	71.0	0.1587
M1	88	10.2	32	36.4	56	63.6
Tumor Stage^a
I	76	9.1	19	25.0	57	75.0	0.4453
II	366	43.7	107	29.2	259	70.8
III	307	36.7	91	29.6	216	70.4
IV	88	10.5	32	36.4	56	63.6
Extra Nodal Ext.^a
Present	262	33.2	92	35.1	170	64.9	0.0041
Absent	527	66.8	133	25.2	394	74.8
LVI^a
Present	350	41.0	110	31.4	240	68.6	0.1411
Absent	504	59.0	135	26.8	369	73.2
Histological Grade ^a
Well differentiated	72	7.6	10	13.9	62	86.1	<0.0001
Moderately differentiated	489	51.3	123	25.1	366	74.9
Poorly differentiated	393	41.2	150	38.2	243	61.8
Histology^a
Infiltrating Ductal Carcinoma	878	93.7	272	31.0	606	69.0	0.0002
Infiltrating Lobular	43	4.6	3	7.0	40	93.0
Mucinous Ca	16	1.7	2	12.5	14	87.5
Triple Negative^a
No	815	84.9	225	27.6	590	72.4	0.0019
Yes	145	15.1	59	40.7	86	59.3
Ki-67 IHC^a
High	610	64.3	214	35.1	396	64.9	<0.0001
Low	339	35.7	66	19.5	273	80.5
PARP^a
High	433	45.2	159	36.7	274	63.3	<0.0001
Low	525	54.8	125	23.8	400	76.2
phos_AKT (473)^a
Negative	728	77.4	181	24.9	547	75.1	<0.0001
Positive	212	22.6	100	47.2	112	52.8
Survival
OS 5 Years				71.8		82.8	0.0005

^aData was not available (NA) for some cases: Tumor size (NA = 25), Lymph nodes (NA = 62), Metastasis (NA = 100), Tumor Stage (NA = 127), Extra Nodal Ext. (NA = 175), LVI (NA = 110), Histological Grade (NA = 10), Histology (NA = 27), Triple Negative (NA = 04), Ki-67 (NA = 15), PARP (NA = 06), & phos. AKT(473) (NA = 24)

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com